RE:RE:RE:I have a 40 page LABS research / valuation report available I am impressed, just standing back as an observer, how Danny has better insights than the CEO of LABS. I'm really impressed, but carry on because no one knows how much market share the generic version of Epidiolex is going to take away from GW nor what the structure of the contract terms and conditions are between Medipharm Labs and their global pharma partner. If this was fishing, I'd have a bucket full of suckers already ;-)